Compare ClearPoint Neuro Inc (CLPT) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Wendys Co — how do they compare? ClearPoint Neuro Inc trades at $15.86 (market cap $478.63M), while Wendys Co trades at $7.49 (market cap $1.41B). The key difference: Wendys Co is far larger — about 2.9× ClearPoint Neuro Inc's market cap, and Wendys Co pays a 7.55% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | WEN | |
|---|---|---|
Market Cap | $478.63M | $1.41B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.60 | $11.33 |
52-Week Low | $8.66 | $6.17 |
Enterprise Value | $506.63M | $5.23B |
Dividend Yield | — | 7.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
Wendy's (WEN) trades at $7.50, down 0.66% on the day, with a bullish technical signal and recent meme-driven momentum. The stock shows strong valuation metrics with a P/E of 9.74 and P/S of 0.65, but faces declining net income margins, falling to 7.58% in 2025. Recent earnings beats and a 7.1% dividend yield attract income investors, while Project Fresh initiatives aim to counter traffic and cost pressures.
Outlook remains mixed: low valuation and retail enthusiasm offer upside, but margin compression and high debt pose risks. Analyst consensus is cautious with a $7.96 price target, suggesting limited near-term growth. Key catalysts include Q2 2026 results on August 7 and international expansion progress, though competitive and inflationary headwinds persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
